MEDIPOST Inc. is a Cambridge, Massachusetts-based biotechnology company focused on creating allogeneic, umbilical cord blood-derived mesenchymal stem cell (MSC) therapies for patients suffering from inflammation-driven degenerative diseases. Its lead candidate targets symptomatic cartilage defects in knee osteoarthritis, leveraging biologically young cells that can be manufactured at scale while offering immune tolerance benefits. Built on a proprietary stem-cell technology platform, the company aims to deliver scalable, off-the-shelf regenerative treatments. Management plans to initiate a U.S. Phase III clinical trial for the knee osteoarthritis program in early 2026, marking its transition into late-stage development. A recent $140 million funding infusion will be used to expand scientific and operational capabilities, build infrastructure, and scale manufacturing processes in preparation for this trial. Support from prominent Korean growth equity investors underscores external confidence in the company’s scientific rigor and global expansion strategy. Although revenue and user metrics have not been disclosed, the new capital provides a substantial runway to advance MEDIPOST’s pipeline through pivotal studies.

Total raised

$140M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2026